You are here: Industry Insights > HCV

News List

Gilead’s Phase II study showed 99% HCV cure rates europeanpharmaceuticalreview
April 27, 2017
Gilead Sciences’ Phase II studies demonstrated HCV cure rates of 99% in children aged 6 to 11 years, and 100% in adult patients co-infected with HCV and hepatitis B virus (HBV).
AbbVie’s HCV/ compensated cirrhosis drug achieved 99% SVR12 rate europeanpharmaceuticalreview
April 25, 2017
AbbVie announced that 99% (145/146) of chronic hepatitis C virus (HCV) infected patients with genotype 1, 2, 4, 5 or 6 and compensated cirrhosis (Child-Pugh A) achieved sustained virologic response...
FDA Approves Two Hepatitis C Drugs for Pediatric Patients americanpharmaceuticalreview
April 11, 2017
The U.S. Food and Drug Administration has approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were previously approved to treat
MRC Technology licenses antibody to Newsummit Biopharma for development of Hepatitis C virus infecti pharmaasia
March 27, 2017
MRC Technology announced it has licensed an antibody to Newsummit Biopharma for development of a novel therapeutic for treatment of Hepatitis C virus (HCV) infection.
British Columbia to provide public access to Gilead Sciences’ Epclusa for genotype 1-6 HCV pharmaceutical-technology
March 24, 2017
British Columbia (BC) has listed Gilead Sciences Canada’s Epclusa (sofosbuvir / velpatasvir) tablets on a public drug plan to treat all six genotypes of chronic hepatitis C virus (HCV) infection.
Gilead Sciences’ MAA for chronic hepatitis C therapy validated in Europe pharmaceutical-technology
January 25, 2017
The European Medicines Agency (EMA) has validated Gilead Sciences’ marketing authorisation application (MAA) for investigational Chronic Hepatitis C Therapy Sofosbuvir / Velpatasvir / Voxilaprevir (SOF / VEL / VOX).

Previous page 1 2 3 4 Next page